PPMonitor checks laboratory air quality
Enables effective and flexible management of indoor air quality
The PPMonitor, from the Caernarfon, Wales firm, can continuously detect, measure and record temperature, humidity, formaldehyde, nitrogen dioxide, carbon monoxide, carbon dioxide, sulphur dioxide, ozone, ammonia and TVOCs.
The device incorporates a variety of advanced gas sensor technologies to monitor the target gases including NDIR, PID and electrochemical sensors.
The wireless units communicate via the Zigbee wireless mesh network, which can be extended by adding repeater nodes or additional PPMonitor or Mini PPMonitor units. Each unit can be configured with unique sensor specifications if required, allowing complete monitoring of the cleanroom air environment.
PPMonitor Units can be wirelessly connected to a Building Management System, in which BMS software allows the entire wireless system to be managed from a single PC. The BMS can activate and control air conditioning and ventilation systems; it can also turn on/off heating and trigger building alarms, if required.
All recorded data is stored automatically with dedicated software, which enables the data to be viewed graphically and produces reports and statistical data. Analysis of the recorded data over time allows for more efficient management of resources and energy.
You may also like
Regulatory
Overcoming CMC challenges in cell and gene therapy: part II
Read moreCertara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Trending Articles
You may also like
Regulatory
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Manufacturing
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory
The key role of IVDs in healthcare: challenges to commercialisation and access
In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment